Dupont Jakob 4
4 · Pyxis Oncology, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Pyxis Oncology Director Dupont Jakob Exercises Options, Sells Shares
What Happened
Dupont Jakob, a director of Pyxis Oncology (PYXS), exercised 35,000 stock options and sold 35,000 common shares on June 30, 2026. The exercise cost reported was $1.60 per share (total $56,000). The shares were sold in multiple trades at a weighted average price of $3.06 per share, yielding proceeds of $107,100. The filing also reports a separate derivative disposition of 35,000 shares at $0.00 (no further detail provided in the filing).
Key Details
- Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely).
- Exercise: 35,000 options exercised at $1.60/share — total exercise cost $56,000. (Code M)
- Sale: 35,000 shares sold at weighted avg $3.06/share — total proceeds $107,100. (Code S)
- Report notes: sales executed under a Rule 10b5-1 trading plan adopted Sept 24, 2025 (F1). Sales executed in multiple trades with prices ranging $3.00–$3.36 (F2, F3).
- Option award details: Award vests in three equal annual tranches from Aug 23, 2023 (vesting commencement Aug 23, 2024) per filing (F4).
- Shares owned after the transactions: not disclosed in the information provided.
Context
This filing shows an option exercise followed by immediate sale of the resulting shares, commonly a cashless exercise/sell pattern and here executed under a pre-established 10b5-1 plan (which typically schedules trades to avoid timing questions). The zero-price derivative disposition is listed in the filing but not explained further in the report. This is a routine director transaction; the filing does not state any change in board status or other corporate developments.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-06-30$1.60/sh+35,000$56,000→ 73,741 total - Sale
Common Stock
[F1][F2][F3]2026-06-30$3.06/sh−35,000$107,100→ 38,741 total - Exercise/Conversion
Stock Option (Right to Buy)
[F4]2026-06-30−35,000→ 357,461 totalExercise: $1.60Exp: 2033-09-22→ Common Stock (35,000 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025.
- [F2]Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4.
- [F3]The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36.
- [F4]Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).